Testing cosibelimab for advanced skin cancer in specific patients
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial tests an immunotherapy drug called cosibelimab for patients with advanced cutaneous squamous cell carcinoma who have either had a kidney transplant or have a blood cancer like lymphoma or myeloma. The goal is to see if it can shrink tumors when surgery or radiation is not an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of skin cancer called cutaneous squamous cell carcinoma that cannot be treated with surgery or radiation, or has come back after these treatments.
- You must have received a kidney transplant at least 6 months ago or have a blood cancer such as chronic leukemia, lymphoma, or multiple myeloma.
- You must be 18 years or older and have adequate kidney, liver, and bone marrow function.
- You must not have had certain immunotherapy drugs in the past year or certain other cancer treatments in the past 6 months.
- You must not have an active autoimmune disease requiring high-dose steroids.
- You must agree to use effective contraception during and for 4 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a personalized cell therapy called TIL (tumor-infiltrating lymphocytes) for people with advanced skin cancers that have not responded to immunotherapy. Doctors take your tumor cells, grow immune cells from them, and then infuse them back to fight the cancer.
This trial tests if two immunotherapy drugs, nivolumab and relatlimab, given before surgery can help shrink a type of skin cancer called cutaneous squamous cell carcinoma. It's for people whose cancer can be removed with surgery.
This trial tests a combination of an immunotherapy drug (cemiplimab) and a special kind of radiation for a type of skin cancer called cutaneous squamous cell carcinoma. It is designed for people whose cancer has come back or is hard to treat with standard surgery or radiation.
This trial tests a new drug (iSCIB1+) combined with two standard immunotherapy drugs (ipilimumab and nivolumab) as the first treatment for advanced melanoma that cannot be removed by surgery. The goal is to see if adding iSCIB1+ helps the immune system fight the cancer better.
This trial tests a very short course of immunotherapy (nivolumab) before standard surgery for patients with certain types of advanced or hard-to-treat skin cancer (cutaneous squamous cell carcinoma). The goal is to see if this approach can reduce the need for extensive or disfiguring surgery.
This early-phase study tests whether adding immunotherapy (nivolumab and ipilimumab) to prednisone and sirolimus can control advanced skin cancers in people with kidney transplants. It aims to see how well the treatment works and how safe it is for transplant recipients.
Hear when a new Cutaneous Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.